Recruiting
Phase 3

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Sponsor:

Amgen

Code:

NCT03836040

Conditions

Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Erenumab Dose 1

Erenumab Dose 2

Erenumab Dose 3

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information